Annals of Oncology Advance Access originally published online on April 7, 2005
Annals of Oncology 2005 16(5):707-715; doi:10.1093/annonc/mdi158
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
1 Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada; 2 Massachusetts General Hospital Cancer Center, Boston, MA, USA; 3 Healthy Heart Program, St Paul's Hospital, Vancouver, BC; 4 National Cancer Institute of Canada, Clinical Trials Group, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada; 5 Mayo Clinic, Rochester, MN; 6 Mayo Clinic, Jacksonville, FL, USA
* Correspondence to: Dr K. M. Wasan, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall Vancouver, British Columbia V6T 1Z3, Canada. Tel: +1-604-822-4889; Fax: +1-604-822-3035; Email: kwasan{at}interchange.ubc.ca
Background:: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L).
Patients and methods:: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing 
5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial.
Results:: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P=0.049), in LDL cholesterol at 12 months (P=0.033) and triglycerides at 24 months (P=0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups.
Conclusions:: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy.
Key words: letrozole, primary breast cancer, postmenopausal women, serum lipids, tamoxifen
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. MELICHAR, H. KALABOVA, L. KRCMOVA, L. URBANEK, R. HYSPLER, D. SOLICHOVA, K. MELICHAROVA, M. PECKA, and Z. ZADAK Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma Anticancer Res, August 1, 2009; 29(8): 3337 - 3346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Markopoulos, A. Polychronis, U. Dafni, D. Koukouras, V. Zobolas, E. Tzorakoleftherakis, G. Xepapadakis, and H. Gogas Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy Ann. Onc., January 1, 2009; 20(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Ingle, D. Tu, J. L. Pater, H. B. Muss, S. Martino, N. J. Robert, M. J. Piccart, M. Castiglione, L. E. Shepherd, K. I. Pritchard, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Ann. Onc., May 1, 2008; 19(5): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Hadji Menopausal symptoms and adjuvant therapy-associated adverse events Endocr. Relat. Cancer, March 1, 2008; 15(1): 73 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Moy, D Tu, J. Pater, J. Ingle, L. Shepherd, T. Whelan, and P. Goss Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Ann. Onc., November 1, 2006; 17(11): 1637 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Perez Appraising Adjuvant Aromatase Inhibitor Therapy Oncologist, November 1, 2006; 11(10): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kendall and M. Dowsett Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr. Relat. Cancer, September 1, 2006; 13(3): 827 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Come Aromatase Inhibitors and Breast Cancer Treatment--Reply JAMA, August 9, 2006; 296(6): 651 - 651. [Full Text] [PDF]
|
|
|
|
|
|
P. D. Ryan and P. E. Goss Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Oncologist, July 1, 2006; 11(7): 718 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Ingle Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer Clin. Cancer Res., February 1, 2006; 12(3): 1031s - 1036s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar and J. Cuzick Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data Clin. Cancer Res., February 1, 2006; 12(3): 1037s - 1048s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist, February 1, 2006; 11(2): 111 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Breast International Group (BIG) 1-98 Collabor A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer N. Engl. J. Med., December 29, 2005; 353(26): 2747 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tondini and R. Labianca Tailoring a tailored treatment: the importance of fine-tuning on the patient Ann. Onc., May 1, 2005; 16(5): 683 - 685. [Full Text] [PDF]
|
|